IAVI Report

The battle against HIV/AIDS lost another great soldier recently with the passing of Australian immunologist and clinician David Cooper on March 18. Cooper was a pioneering scientist and champion for HIV treatment and prevention, and he left an indelible mark on the field he dedicated his career to. “He had a great skill in knowing…

Jonathan Quick describes how the right mix of science, funding, leadership, and communication can come together to secure the world against future epidemics.

Influenza, like HIV, is a highly variable menace. A particularly bad flu season has researchers seeking ways to make a better vaccine, and in doing so, there may be lessons from, and for, HIV vaccine research.

Several areas of progress in using antibodies for HIV prevention were showcased at the recent Keystone Symposia.

We are at a defining moment in the history of HIV vaccine research. It is not an exaggeration to also propose that, thanks to the fruits of decades of HIV vaccine research and development efforts, we are entering a new era of vaccinology more broadly. A new generation of HIV vaccine candidates is poised to…

Coalition awards US$174 million in grants for research targeting Nipah virus, Lassa fever, and MERS.

The vaccine world lost another of its great leaders recently with the passing of Adel Mahmoud, a physician, scientist, and professor who played a critical role in the development of many innovative and lifesaving vaccines during his long and successful career. He is remembered by his friends and colleagues as a tireless champion of public…

The pandemic isn’t over, but that might be what donors are hearing.

In a few weeks, the AIDS 2018 meeting will kick off in Amsterdam. It will be the 22nd annual conference, and remains the largest international gathering focused on a single public health issue. This year, one message that will come out loud and clear is that more than 30 years later, AIDS isn’t over. As…

Marianne Mureithi is part of a team of researchers that just received highly competitive funding to study mucosal immune responses to HIV in Kenya.

Drone delivery may help overcome the challenge of getting medicines and vaccines to hard-to-reach populations.

Maria Grazia Pau, senior director, compound development team leader for HIV vaccine programs at the Janssen Pharmaceutical Companies of Johnson & Johnson, talks with IAVI Report about the start of the company’s Phase III Mosaico trial.